GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanologica AB (OSTO:NICA) » Definitions » EV-to-FCF

Nanologica AB (OSTO:NICA) EV-to-FCF : -1.93 (As of Dec. 14, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Nanologica AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Nanologica AB's Enterprise Value is kr147.35 Mil. Nanologica AB's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was kr-76.34 Mil. Therefore, Nanologica AB's EV-to-FCF for today is -1.93.

The historical rank and industry rank for Nanologica AB's EV-to-FCF or its related term are showing as below:

OSTO:NICA' s EV-to-FCF Range Over the Past 10 Years
Min: -24.08   Med: -5.24   Max: -0.48
Current: -2.05

During the past 10 years, the highest EV-to-FCF of Nanologica AB was -0.48. The lowest was -24.08. And the median was -5.24.

OSTO:NICA's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 8.19 vs OSTO:NICA: -2.05

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-14), Nanologica AB's stock price is kr1.785. Nanologica AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was kr-2.156. Therefore, Nanologica AB's PE Ratio (TTM) for today is At Loss.


Nanologica AB EV-to-FCF Historical Data

The historical data trend for Nanologica AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanologica AB EV-to-FCF Chart

Nanologica AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.69 -6.36 -7.14 -5.50 -6.45

Nanologica AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.57 -6.45 -3.69 -3.77 -1.34

Competitive Comparison of Nanologica AB's EV-to-FCF

For the Biotechnology subindustry, Nanologica AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanologica AB's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanologica AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Nanologica AB's EV-to-FCF falls into.



Nanologica AB EV-to-FCF Calculation

Nanologica AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=147.345/-76.337
=-1.93

Nanologica AB's current Enterprise Value is kr147.35 Mil.
Nanologica AB's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-76.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nanologica AB  (OSTO:NICA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Nanologica AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.785/-2.156
=At Loss

Nanologica AB's share price for today is kr1.785.
Nanologica AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-2.156.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Nanologica AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Nanologica AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanologica AB Business Description

Traded in Other Exchanges
Address
Forskargatan 20G, Sodertalje, SWE, SE-151 36
Nanologica AB develops and manufactures nanoporous silica particles for life science applications. It focuses on two areas: Drug Development and Chromatography. The company's drug delivery platforms are NLAB Spiro and NLAB Silica, which focus on producing medicines for the benefit of patients. Its geographical segments are Sweden, China, India, the United States, and the Rest of the world.

Nanologica AB Headlines

No Headlines